Cancer and GI Mucositis
Radiation and chemotherapy are important oncology treatments, but affect off-target organs and can injure the mucosal membrane of gastrointestinal (GI) tract. These therapies break down the epithelial cells lining the GI tract, leaving the mucosal tissue open to ulceration, inflammation, and infection.
As a side effect of their cancer treatment, patients may experience a wide array of debilitating symptoms such as nausea, diarrhea, or gut infections caused by damage to the stomach and intestines. These symptoms reduce the patient’s tolerance for therapy and are the most common dose limiting factor in cancer radiation therapy.
SYGN305: relief from gut injury caused by cancer therapies
Synedgen is developing SYGN305, an innovative therapeutic to repair mucosal/intestinal injury, prevent infection and reduce inflammation resulting from radiation and chemotherapy. This drug is designed to reduce toxicity to the GI tract from cancer treatments, allowing patients to safely tolerate higher treatment doses needed to aggressively treat their cancer.
In animal models, SYGN305 reduces chemical or radiation-induced mortality by restoring mucosal defenses and barriers and preventing bacterial translocation that could otherwise result in sepsis. Deriving from our glycochemistry platform, SYGN305 has been shown to promote healing and reduce inflammation at the damaged tissue surface. In addition, this restoration of a healthy gut environment restored normal commensal flora and prevented overgrowth of pathogenic bacteria.
Synedgen is well positioned to lead the industry in the advancement of modified glycopolymers for therapeutic use in cancer supportive care. SYGN305 is being developed for acute and chronic GI mucositis, with expansion indications that include graft-versus-host disease, and GI damage caused by acute radiation syndrome.